Beyond CTLA-4 and PD-(L)1 blockade, there is interest in targeting alternative immune-checkpoints in HCC to build on the success of combination therapy and overcome resistance mechanisms to ICI-based regimens. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.